975 results match your criteria Clinical Colorectal Cancer[Journal]


Cancer Stemness, Immune Cells, and Epithelial-Mesenchymal Transition Cooperatively Predict Prognosis in Colorectal Carcinoma.

Clin Colorectal Cancer 2018 May 26. Epub 2018 May 26.

Department of Pathology, Key Laboratory of Disease Proteomics of Zhejiang Province, School of Medicine, Zhejiang University, Hangzhou, China. Electronic address:

Background: Tumor tissues consist of heterogeneous cancer cells and stroma cells, including cancer stem cells and immune cells. Epithelial-mesenchymal transition (EMT) programs closely associate with acquisition of stemness. We investigated for the first time the clinical significance of combining cancer stem cells, immune cells, and EMT traits. Read More

View Article
May 2018
2 Reads

Comparative Effectiveness of Neoadjuvant Chemoradiation Versus Upfront Surgery in the Management of Recto-Sigmoid Junction Cancer.

Clin Colorectal Cancer 2018 May 17. Epub 2018 May 17.

Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA.

Introduction: The optimal management of locally advanced recto-sigmoid cancer is unclear. Although some experts advocate for upfront surgery, others recommend neoadjuvant chemoradiation followed by surgery. We used the National Cancer Database to characterize patterns-of-care and overall survival (OS) associated with these treatment strategies. Read More

View Article

Association Between Height and Clinical Outcome in Metastatic Colorectal Cancer Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE-3 Study.

Clin Colorectal Cancer 2018 May 10. Epub 2018 May 10.

Comprehensive Cancer Center, Ludwig-Maximilian-University of Munich, Munich, Germany.

Background: Previous studies have found significant relationships between height and colorectal cancer (CRC) risk. Increased growth has been associated with activated pathways such as insulin-like growth factor 1. This study examined the impact of height on outcomes in metastatic CRC patients enrolled onto the FIRE-3 study, a randomized phase 3 clinical trial. Read More

View Article
May 2018
2 Reads

Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer.

Clin Colorectal Cancer 2018 May 19. Epub 2018 May 19.

Division of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan. Electronic address:

Purpose: To evaluate a prognostic and predictive value of HER2 amplification in patients with metastatic colorectal cancer (mCRC).

Patients And Methods: Patients with mCRC who underwent surgical resection of the primary tumor and who received best supportive care with or without palliative chemotherapy between 2005 and 2015 were included. HER2 immunohistochemistry was performed using formalin-fixed, paraffin-embedded primary tumor specimens. Read More

View Article

Inflammation-Modulating Effect of Butyrate in the Prevention of Colon Cancer by Dietary Fiber.

Clin Colorectal Cancer 2018 May 17. Epub 2018 May 17.

Medlab Clinical, Sydney, Australia; The University of Sydney, Sydney Medical School, Sydney, Australia. Electronic address:

The intestinal microbiota plays key roles in human health, and adverse dysbiosis shifts of the microbiota have been associated with chronic diseases, including large bowel cancer. High-fiber diets may reduce the risk for large bowel cancer in association with gut microbiota modulation and butyrate production. Butyrate can inhibit histone deacetylases and associated signaling pathways in cultured cancer cells, promoting cancer cell apoptosis. Read More

View Article

Safety and Efficacy of Oxaliplatin Doublet Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer.

Clin Colorectal Cancer 2018 May 31. Epub 2018 May 31.

Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, Australia; School of Biological Sciences, University of Wollongong, Wollongong, Australia; CONCERT - Centre for Oncology Education and Research Translation, New South Wales, Australia.

Background: Colon cancer is common in the elderly, but owing to under representation in clinical trials, the benefit of standard therapies is uncertain in this age group. We aimed to clarify the efficacy and complications of adjuvant oxaliplatin and fluoropyrimidine chemotherapy for patients 70 years and older with stage III colon cancer.

Patients And Methods: All patients with stage III colon adenocarcinoma were identified from an Australian cancer registry (2006-2013). Read More

View Article

Real-world Treatment Patterns Among Patients With Colorectal Cancer Treated With Trifluridine/Tipiracil and Regorafenib.

Clin Colorectal Cancer 2018 Apr 21. Epub 2018 Apr 21.

Dana-Farber Cancer Institute, Boston, MA; Yale Cancer Center, New Haven, CT.

Background: Trifluridine/tipiracil (FTD/TPI) and regorafenib (REG) prolong survival in refractory metastatic colorectal cancer (mCRC) and have similar indications with different side-effect profiles. The present study compared real-world treatment patterns with FTD/TPI and REG for mCRC in a large, representative US claims database.

Materials And Methods: Retrospective data from the US Symphony Health Solutions' Integrated Dataverse database were analyzed for adult mCRC patients receiving FTD/TPI or REG from October 2014 to July 2016. Read More

View Article

Nucleotide Excision Repair Capacity and XPC and XPD Gene Polymorphism Modulate Colorectal Cancer Risk.

Clin Colorectal Cancer 2018 Jun 10;17(2):e435-e441. Epub 2017 Jan 10.

Department of General and Colorectal Surgery, Medical University of Lodz, Lodz, Poland.

Background: Colorectal cancer (CRC) is leading malignant tumors to occur mainly in industrialized countries, where it exhibits one of the highest mortality rates. Up to 80% of all CRCs characterize a chromosomal instability (CIN) phenotype. The main challenge faced by scientist is to reveal the mechanism of CIN development. Read More

View Article

Adjuvant Management of Pathologic Node-Positive Disease After Definitive Surgery for Clinical T1-2 N0 Rectal Cancer.

Clin Colorectal Cancer 2018 Apr 21. Epub 2018 Apr 21.

Department of Radiation Oncology, Houston Methodist Hospital, Houston, TX.

Introduction: Patients with cT1-2N0M0 rectal cancer are often treated with up-front surgical resection, with adjuvant treatment reserved for patients upstaged with pathologic node-positive (pN+) disease at surgery. This study evaluates practice patterns and clinical outcomes when comparing different forms of adjuvant treatment for this patient population.

Methods: The National Cancer Data Base was queried for cT1-2N0M0 rectal cancer patients between 2004 and 2015 with postoperative pN+ disease treated without neoadjuvant treatment. Read More

View Article

Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer.

Clin Colorectal Cancer 2018 Mar 21. Epub 2018 Mar 21.

Department of Oncology, Center of Oncology, Clinical Hospital Center Split, Split, Croatia.

Introduction: Tumor rat sarcoma gene (RAS) status is a negative predictive biomarker for anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer (mCRC). We analyzed outcomes according to RAS and v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutational status, and evaluated early tumor shrinkage (ETS) and depth of response (DpR) for patients with wild type RAS.

Patients And Methods: Patients with confirmed metastatic colon or rectum adenocarcinoma, wild type Kristen rat sarcoma gene tumor exon 2 status, clinical/radiologic disease progression or toxicity during irinotecan or oxaliplatin treatment, and no previous anti-EGFR therapy were randomized 1:1 to receive best supportive care (BSC) with or without panitumumab (6. Read More

View Article

Effect of Neoadjuvant Therapy and Rectal Surgery on Health-related Quality of Life in Patients With Rectal Cancer During the First 2 Years After Diagnosis.

Clin Colorectal Cancer 2018 Mar 21. Epub 2018 Mar 21.

Imaging Division, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands; University of Utrecht, Utrecht, The Netherlands.

Introduction: Rectal cancer surgery with neoadjuvant therapy is associated with substantial morbidity. The present study describes the course of quality of life (QOL) in rectal cancer patients in the first 2 years after the start of treatment.

Patients And Methods: We performed a prospective study within a colorectal cancer cohort including rectal cancer patients who were referred for neoadjuvant chemoradiation or short-course radiotherapy and underwent rectal surgery. Read More

View Article
March 2018
1 Read

Review of Blood-Based Colorectal Cancer Screening: How Far Are Circulating Cell-Free DNA Methylation Markers From Clinical Implementation?

Clin Colorectal Cancer 2018 Jun 2;17(2):e415-e433. Epub 2018 Mar 2.

Department of Molecular Medicine, MOMA, Aarhus University, Aarhus, Denmark. Electronic address:

Colorectal cancer (CRC) is a leading cause of cancer related deaths worldwide, and late stages (III-IV) in particular have low 5-year survival rates. Stage shifting by CRC screening programs has proven effective by decreasing morbidity and mortality and in many countries national CRC screening programs have been implemented. Currently, European, Asian, and American authorities recommend screening for CRC using fecal occult blood testing, sigmoidoscopy, or colonoscopy. Read More

View Article
June 2018
6 Reads

Predictive Nomogram for Recurrence of Stage I Colorectal Cancer After Curative Resection.

Clin Colorectal Cancer 2018 Mar 29. Epub 2018 Mar 29.

Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. Electronic address:

Background: Patients with stage I colorectal cancer (CRC) have excellent prognosis after curative surgery. However, approximately 5% to 10% of patients experience recurrence and have a poor prognosis. Because the incidence of stage I CRC is increasing with active screening programs worldwide, a more accurate and easy-to-use predictive tool for recurrence is becoming more important. Read More

View Article
March 2018
1 Read

Tolerability, Safety, and Outcomes of Neoadjuvant Chemoradiotherapy With Capecitabine for Patients Aged ≥ 70 Years With Locally Advanced Rectal Cancer.

Clin Colorectal Cancer 2018 Mar 8. Epub 2018 Mar 8.

Department of Internal Medicine/Oncology, St Antonius Hospital Nieuwegein, Nieuwegein, Netherlands.

Introduction: In studies of colorectal cancer, the elderly have been frequently underrepresented because comorbid conditions and functional status often lead to study exclusion. For elderly patients with an indication for neoadjuvant chemoradiotherapy (nCRT), physicians usually decide using clinical factors whether nCRT should be offered. The aim of the present retrospective study was to assess the tolerability of nCRT with capecitabine and the surgical outcomes in patients aged ≥ 70 years with locally advanced rectal cancer. Read More

View Article
March 2018
1 Read

A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial.

Clin Colorectal Cancer 2018 Mar 8. Epub 2018 Mar 8.

Department of Oncology, Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada.

Background: Oncolytic reovirus pelareorep might preferentially infect and destroy rat sarcoma (RAS)-activated cells, and has preclinical and early clinical activity against colorectal cancer (CRC).

Patients And Methods: After a 6-patient safety run-in, 103 patients with metastatic CRC were randomly assigned to standard first-line leucovorin/5-FU/oxaliplatin (FOLFOX6)/bevacizumab (FOLFOX/BEV) every 2 weeks with (n = 51) or without (n = 52) pelareorep 3 × 10 tissue culture infective dose 50 on days 1 to 5 (cycles 1, 2, 4, and alternate cycles thereafter). The primary end point was progression-free survival (PFS). Read More

View Article
March 2018
1 Read

Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study.

Clin Colorectal Cancer 2018 Mar 21. Epub 2018 Mar 21.

Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy.

Background: Comorbidity has a detrimental effect on cancer survival, however, it is difficult to disentangle its direct effect from its influence on treatment choice. In this study we assessed the effect of comorbidity on survival in patients who received standard treatment for resected stage II and III colorectal cancer (CRC).

Patients And Methods: In total, 230 CRC patients, 68 rectal (29. Read More

View Article
March 2018
1 Read

Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.

Clin Colorectal Cancer 2018 Mar 14. Epub 2018 Mar 14.

Division of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA. Electronic address:

Background: No biomarkers exist to predict benefit from antiangiogenic therapy in metastatic colorectal cancer patients. ACVRL1 (activin receptor like-protein 1) encodes for ALK1, a member of the transforming growth factor-β receptor family, which directs pathologic angiogenesis. We examined the intratumoral expression of ACVRL1 and other angiogenesis pathway-related genes to identify molecular markers in the TRIBE study. Read More

View Article
March 2018
1 Read

Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience.

Clin Colorectal Cancer 2018 Mar 8. Epub 2018 Mar 8.

Section of Haematology/Oncology, University of Manitoba, Winnipeg, MB, Canada.

Background: Advanced pancreatic cancer (APC) has a poor prognosis. Current first-line chemotherapy options include FOLFIRINOX (5-fluorouracil, irinotecan, oxaliplatin), NG (nab-paclitaxel, gemcitabine), and GEM (gemcitabine) alone. The optimal second-line regimen is unclear. Read More

View Article
March 2018
1 Read

Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies.

Clin Colorectal Cancer 2018 Mar 8. Epub 2018 Mar 8.

Center for Oncological Research, University of Antwerp, Wilrijk, Belgium; Department of Oncology, Antwerp University Hospital, Edegem, Belgium. Electronic address:

Background: The primary tumor location has a prognostic impact in metastatic colorectal cancer (mCRC). We report the results from retrospective analyses assessing the effect of tumor location on prognosis and efficacy of second- and later-line panitumumab treatment in patients with RAS wild-type (WT) mCRC and on prognosis in all lines of treatment in patients with RAS mutant (MT) mCRC.

Patients And Methods: RAS WT data (n = 483) from 2 randomized phase III panitumumab trials (ClinicalTrials. Read More

View Article
March 2018
1 Read

Meta-analysis of Modified FOLFIRINOX Regimens for Patients With Metastatic Pancreatic Cancer.

Clin Colorectal Cancer 2018 Mar 14. Epub 2018 Mar 14.

Department of Oncology, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.

Background: We performed a meta-analysis of previous reports evaluating the effect of mFIO (modified FOLFIRINOX; leucovorin, 5-fluorouracil, irinotecan, oxaliplatin) regimens in advanced pancreatic cancer.

Materials And Methods: We performed a meta-analysis of reported studies in PubMed, Scopus, and Web of Science (1950-2016) in December 2016. The inclusion criteria were randomized trials, prospective or retrospective cohorts, patients with metastatic pancreatic adenocarcinoma, the use of mFIO or FOLFIRINOX (FIO) chemotherapy, and available information for ≥ 1 efficacy endpoint (response rate, progression-free survival, and/or overall survival). Read More

View Article
March 2018
1 Read

Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib.

Clin Colorectal Cancer 2018 Jun 27;17(2):e395-e414. Epub 2018 Feb 27.

Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA. Electronic address:

Background: The C-C motif chemokine ligand 5/C-C motif chemokine receptor 5 (CCL5/CCR5) pathway has been shown to induce endothelial progenitor cell migration, resulting in increased vascular endothelial growth factor A expression. We hypothesized that genetic polymorphisms in the CCL5/CCR5 pathway predict efficacy and toxicity in patients with metastatic colorectal cancer (mCRC) treated with regorafenib.

Patients And Methods: We analyzed genomic DNA extracted from 229 tumor samples from 2 different cohorts of patients who received regorafenib: an evaluation cohort of 79 Japanese patients and a validation cohort of 150 Italian patients. Read More

View Article
June 2018
3 Reads

Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study.

Clin Colorectal Cancer 2018 Mar 8. Epub 2018 Mar 8.

Medical Oncology Unit, ARNAS Garibaldi, Catania, Italy.

Background: Aflibercept combined with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) as second-line treatment of metastatic colorectal cancer (mCRC) significantly improved survival compared with FOLFIRI alone in the pivotal VELOUR (aflibercept vs. placebo in combination with irinotecan and 5-fluorouracil in the treatment of patients with metastatic colorectal cancer after failure of an oxaliplatin-based regimen) trial. No quality-of-life assessment was performed in VELOUR; therefore, the ASQoP (Aflibercept Safety and Quality-of-Life Program) trial was designed to capture the safety and health-related quality of life (HRQL). Read More

View Article
March 2018
1 Read

Mutation and Methylation Analysis of Circulating Tumor DNA Can Be Used for Follow-up of Metastatic Colorectal Cancer Patients.

Clin Colorectal Cancer 2018 Jun 22;17(2):e369-e379. Epub 2018 Feb 22.

Center for Oncological Research (CORE), University of Antwerp, Antwerp, Belgium; Department of Oncology, Antwerp University Hospital, Antwerp, Belgium. Electronic address:

Background: Targeted therapies, although contributing to survival improvement in metastatic colorectal cancer (mCRC), are expensive and may cause adverse effects. Therefore, confirming that patients are responding to these therapies is extremely important. Currently, follow-up is performed using radiographic evaluation, which has its limitations. Read More

View Article
June 2018
2 Reads

Significance of PITX2 Promoter Methylation in Colorectal Carcinoma Prognosis.

Clin Colorectal Cancer 2018 Jun 23;17(2):e385-e393. Epub 2018 Feb 23.

Department of Otolaryngology, Head and Neck Surgery, University Hospital Bonn, Bonn, Germany.

Background: New treatment modalities and a growing understanding of the complex genetic tumor landscape have improved the outcome of colorectal cancer (CRC) patients. Nonetheless, more individualized treatment regimens, taking individual tumor characteristics into account, have been recently postulated and prognostic biomarkers are needed. We therefore evaluated the prognostic potential of paired-like homeodomain transcription factor 2 (PITX2) promoter methylation in CRC patients. Read More

View Article
June 2018
2 Reads

c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival.

Clin Colorectal Cancer 2018 Mar 2. Epub 2018 Mar 2.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address:

Introduction: Increased mesenchymal-epithelial transition factor gene (c-MET) expression in several human malignancies is related to increased tumor progression and is a new potential drug target for several types of cancers. In the present study, we investigated the incidence of c-MET overexpression and its prognostic significance in patients with colorectal cancer (CRC).

Patients And Methods: We retrospectively reviewed the data from 255 stage IV CRC patients who had results from a c-MET immunohistochemical test at Samsung Medical Center. Read More

View Article
March 2018
6 Reads

Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review.

Clin Colorectal Cancer 2018 Jun 13;17(2):85-96. Epub 2017 Dec 13.

Jefferson University Hospitals, Philadelphia, PA.

Monoclonal antibody inhibitors of the epidermal growth factor receptor (EGFR) have been shown to improve outcomes for patients with metastatic colorectal cancer (mCRC) without RAS gene mutations. However, treatment with anti-EGFR agents can be associated with toxicities of the skin, nails, hair, and eyes. Because these dermatologic toxicities can result in treatment discontinuation and affect patient quality of life, their management is an important focus when administering anti-EGFR monoclonal antibodies. Read More

View Article
June 2018
1 Read

A Pilot Study of Apatinib as Third-Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer.

Clin Colorectal Cancer 2018 Mar 2. Epub 2018 Mar 2.

Department of Radiation Oncology, The Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang, Jiangsu, People's Republic of China; Tumor Laboratory, The Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang, Jiangsu, People's Republic of China; Lianyungang Clinical College of Nanjing Medical University, Lianyungang, Jiangsu, People's Republic of China. Electronic address:

Background: Antiangiogenic therapy has shown improved clinical outcome in metastatic colorectal cancer (mCRC). After the failure of standard treatments, regorafenib and TAS-102 would be recommended for patients with mCRC, however, they have not been approved in China during this study period.

Patients And Methods: This pilot study aimed to assess the efficacy and safety of apatinib, a novel oral inhibitor targeting vascular endothelial growth factor receptor 2, as third-line treatment for patients with mCRC refractory to standard therapies. Read More

View Article
March 2018
2 Reads

Addressing Racial Disparity in Colorectal Cancer Screening With CT Colonography: Experience in an African-American Cohort.

Clin Colorectal Cancer 2018 Jun 20;17(2):e363-e367. Epub 2018 Feb 20.

Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI.

Background: Incidence and mortality from colorectal cancer (CRC) are higher among African Americans where CRC screening rates lag behind non-Hispanic whites. The purpose of this investigation was to evaluate CT colonography (CTC) performance and outcome measures in an African-American cohort.

Materials And Methods: This study is an institutional review board-approved and Health Insurance Portability and Accountability Act-compliant study. Read More

View Article
June 2018
1 Read

A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer.

Clin Colorectal Cancer 2018 Jun 17;17(2):e323-e329. Epub 2018 Feb 17.

Department of Medical Oncology, IMIBIC. University Hospital Reina Sofia, CIBERONC Instituto de Salud Carlos III, Cordoba, Spain.

Introduction: The aim of this study was to evaluate the efficacy and safety of maintenance therapy with axitinib versus placebo following induction therapy in patients with metastatic colorectal cancer (mCRC).

Patients And Methods: In this double-blinded, phase II trial, patients with mCRC who had not progressed after 6 to 8 months of first-line chemotherapy were randomized to receive axitinib (5 mg twice a day) (arm A) or placebo (arm B).

Results: Forty-nine patients were included: 25 in arm A and 24 in arm B. Read More

View Article
June 2018
1 Read

Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer.

Clin Colorectal Cancer 2018 Jun 31;17(2):140-146. Epub 2018 Jan 31.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address:

Background: Samsung Advance Institute of Technology-301 (SAIT301) is a human immunoglobulin G2 antibody that can specifically target mesenchymal epithelial transition factor (c-MET). This novel antibody has higher priority over hepatocyte growth factors when binding to the Sema domain of c-MET and accelerates the internalization and degradation of c-MET, proving its powerful antitumor activities in intra- as well as extracellular areas.

Materials And Methods: SAIT301 was administered intravenously once every 3 weeks in c-MET overexpressed solid tumor patients, focusing on metastatic colorectal cancer (CRC) according to common clinical phase I criteria. Read More

View Article
June 2018
2 Reads

Efficacy of Mobile Health Care Application and Wearable Device in Improvement of Physical Performance in Colorectal Cancer Patients Undergoing Chemotherapy.

Clin Colorectal Cancer 2018 Jun 17;17(2):e353-e362. Epub 2018 Feb 17.

Department of Physical and Rehabilitation Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. Electronic address:

Background: The use of a mobile health care application, the delivery of health care or health care-related services through the use of portable devices, to manage functional loss, treatment-related toxicities, and impaired quality of life in cancer patients during chemotherapy through supervised self-management has been increasing. The aim of the present study was to evaluate the efficacy and feasibility of comprehensive mobile health care using a tailored rehabilitation program for colorectal cancer patients undergoing active chemotherapy.

Patients And Methods: A total of 102 colorectal cancer patients undergoing chemotherapy underwent 12 weeks of smartphone aftercare through provision of a mobile application and wearable device that included a rehabilitation exercise program and information on their disease and treatment. Read More

View Article
June 2018
1 Read

Regorafenib or Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer? A Perspective on the Basis of Pharmacological Costs.

Clin Colorectal Cancer 2018 Jun 23;17(2):e381-e383. Epub 2018 Feb 23.

Department of Oncology, Mater Salutis Hospital, Legnago, Verona, Italy.

View Article
June 2018
1 Read

Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy.

Clin Colorectal Cancer 2018 Feb 21. Epub 2018 Feb 21.

La Sapienza University, Rome, Italy.

Background: In the CORRECT (patients with metastatic COloRectal Cancer treated with REgorafenib or plaCebo after failure of standard Therapy) trial, regorafenib was proven to extend survival of patients with metastatic colorectal cancer (mCRC) that progressed after all available therapies. Grade 3 to 4 toxicity occurred in 54% of patients, and data on the activity and tolerability of regorafenib in elderly patients were scarce. The aim of this study was to evaluate the efficacy and safety of an alternative schedule, 2-week-on treatment and 1 week-off (2/1 schedule), of regorafenib for elderly patients with mCRC. Read More

View Article
February 2018
1 Read

A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study.

Clin Colorectal Cancer 2018 Jun 9;17(2):147-155. Epub 2018 Feb 9.

Department of Surgery, Shimane Prefectural Central Hospital, Shimane, Japan.

Background: FOLFOXIRI (Fluorouracil, folinate, oxaliplatin, and irinotecan) plus bevacizumab improved progression-free survival (PFS) and overall survival in patients with metastatic colorectal cancer (mCRC), compared with FOLFIRI (fluorouracil, folinate, and irinotecan) plus bevacizumab, but significantly increased the incidences of adverse events. The efficacy and safety profiles of FOLFOXIRI plus bevacizumab in ethnic Asian patients have not been established yet.

Patients And Methods: This study was an open-label, single-arm, multi-centered phase II prospective clinical trial in patients with mCRC who received FOLFOXIRI plus bevacizumab. Read More

View Article
June 2018
3 Reads

Phosphorylation of p70 Ribosomal Protein S6 Kinase β-1 is an Independent Prognostic Parameter in Metastatic Colorectal Cancer.

Clin Colorectal Cancer 2018 Jun 17;17(2):e331-e352. Epub 2018 Feb 17.

Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; German Cancer Consortium, Partner Site University Hospital Essen, Essen, Germany. Electronic address:

Background: Deregulation of signal transduction pathways plays a critical role in oncogenesis of colorectal cancer (CRC) and directly affects sensitivity to targeted therapies. Against this background we developed a comprehensive biomarker profiling program including markers of downstream signaling to study their association with clinical outcomes.

Patients And Methods: A prospectively studied cohort of 160 patients with metastatic CRC was included. Read More

View Article
June 2018
5 Reads

Pattern and Management of Recurrence of Mid-Low Rectal Cancer After Neoadjuvant Intensity-Modulated Radiotherapy: Single-Center Results of 687 Cases.

Clin Colorectal Cancer 2018 Jun 7;17(2):e307-e313. Epub 2018 Mar 7.

Department of Gastrointestinal Surgery, Peking University Cancer Hospital, Beijing, PR China.

Background: The purpose of this study was to retrospectively analyze the pattern and the management of recurrence of rectal cancer treated with 22-fraction intensity-modulated radiation therapy (IMRT).

Patients And Methods: This study included patients who underwent IMRT with gross tumor volume of 50.6 Gy in 22 fractions with concurrent capecitabine treatment over a period of 30 days, after which the patients underwent total mesorectal excision at Peking University Cancer Hospital (2007-2015). Read More

View Article
June 2018
1 Read

Effectiveness of Cetuximab as First-Line Therapy for Patients With Wild-Type KRAS and Unresectable Metastatic Colorectal Cancer in Real-Life Practice: Results of the EREBUS Cohort.

Clin Colorectal Cancer 2018 Jun 31;17(2):129-139. Epub 2018 Jan 31.

Digestive oncology and Gastroenterology Department, Hôpital Haut-Lévêque, CHU de Bordeaux, Pessac, France. Electronic address:

Introduction: Few real-life data are available on cetuximab benefit. The EREBUS cohort was performed to assess metastases resection rate, use, safety, and survival outcomes in wild-type KRAS (Kirsten rat sarcoma viral oncogene) patients with initially unresectable metastatic colorectal cancer (mCRC) treated by cetuximab in real practice.

Patients And Methods: The study cohort comprised patients initiating cetuximab between January 2009 and December 2010 in 65 French centers, with initially unresectable mCRC and wild-type KRAS. Read More

View Article
June 2018
4 Reads

Association of CDX2 Expression With Survival in Early Colorectal Cancer: A Systematic Review and Meta-analysis.

Clin Colorectal Cancer 2018 Jun 15;17(2):97-103. Epub 2018 Feb 15.

Oncology Unit, Oncology Department, ASST Bergamo Ovest, Treviglio, Bergamo, Italy. Electronic address:

CDX2 is a homeobox gene encoding transcriptional factors for intestinal organogenesis and represents a specific marker of colorectal adenocarcinoma (CRC) differentiation. We have evaluated if CDX2 expression is associated with better overall and disease-free survival (OS and DFS) in patients with CRC. PubMed, SCOPUS, EMBASE, The Cochrane Library, and Web of Science (from inception to July 2017) were systematically reviewed for relevant studies on adult patients with CRC where OS and DFS were calculated according to CDX2 expression in uni- or multivariate analysis were included. Read More

View Article
June 2018
1 Read

Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence?

Clin Colorectal Cancer 2018 Jun 7;17(2):e315-e321. Epub 2018 Feb 7.

Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY. Electronic address:

Purpose: To assess clinical characteristics of patients with metastatic pancreas ductal adenocarcinoma (PDAC) and brain metastases (BM), and to assess somatic and germ-line molecular profiles where performed.

Patients And Methods: Patients with PDAC and BM between January 1990 and January 2016 were identified. Molecular characteristics of somatic and germ-line testing where performed in the subset of patients who had provided informed consent. Read More

View Article
June 2018
5 Reads

Survival Impact of CAPOX Versus FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer.

Clin Colorectal Cancer 2018 Jun 7;17(2):156-163. Epub 2018 Feb 7.

Division of Medical Oncology, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address:

Background: Capecitabine and oxaliplatin (CAPOX) and folinic acid, fluorouracil, and oxaliplatin (FOLFOX) are both used in the adjuvant treatment of colon cancer, and while their efficacy is assumed to be similar, they have not been directly compared. We reviewed the toxicity profiles, relative dose intensity (RDI), and survival associated with these regimens across a multi-institutional cohort.

Patients And Methods: We identified 394 consecutively treated patients with stage III colon cancer who received an oxaliplatin-containing regimen. Read More

View Article
June 2018
5 Reads

Incidence, Management, and Implications of Visceral Thrombosis in Pancreatic Ductal Adenocarcinoma.

Clin Colorectal Cancer 2018 Jun 31;17(2):121-128. Epub 2018 Jan 31.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medicine, New York, NY. Electronic address:

Background: Visceral or splanchnic thrombosis is defined as thrombi within the hepatoportal venous system, including portal (PV), mesenteric (MV), and splenic vein (SV), as well as thrombi in renal or gonadal veins. There are limited data to evaluate the prognostic significance, incidence, and clinical management of visceral thromboses in patients with pancreatic ductal adenocarcinoma (PDAC).

Patients And Methods: We conducted an analysis of 95 patients treated at Memorial Sloan Kettering Cancer Center with PDAC who had a visceral thrombosis. Read More

View Article
June 2018
1 Read

Update on Hereditary Colorectal Cancer: Improving the Clinical Utility of Multigene Panel Testing.

Clin Colorectal Cancer 2018 Jun 11;17(2):e293-e305. Epub 2018 Jan 11.

Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, Victoria, Australia; Genetic Medicine and Family Cancer Clinic, Royal Melbourne Hospital, Parkville, Victoria, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Carlton, Victoria, Australia; University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, Victoria, Australia. Electronic address:

Colorectal cancer (CRC), one of the most common cancers, is a major public health issue globally, especially in Westernized countries. Up to 35% of CRCs are thought to be due to heritable factors, but currently only 5% to 10% of CRCs are attributable to high-risk mutations in known CRC susceptibility genes, predominantly the mismatch repair genes (Lynch syndrome) and adenomatous polyposis coli gene (APC; familial adenomatous polyposis). In this era of precision medicine, high-risk mutation carriers, when identified, can be offered various risk management options that prevent cancers and improve survival, including risk-reducing medication, screening for early detection, and surgery. Read More

View Article
June 2018
3 Reads

Frequency of Surveillance and Impact of Surveillance Colonoscopies in Patients With Ulcerative Colitis Who Developed Colorectal Cancer.

Clin Colorectal Cancer 2018 Jun 11;17(2):e289-e292. Epub 2018 Jan 11.

Section of Gastroenterology, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA; Section of Gastroenterology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. Electronic address:

Background: The risk of developing colorectal cancer (CRC) in patients with chronic ulcerative colitis (UC) is increased. The aim of this study was to evaluate if patients who developed CRC in the setting of UC were undergoing guideline-recommended surveillance colonoscopies and to determine the impact of surveillance on the staging of CRC.

Patients And Methods: Data was obtained from the Veterans Affairs healthcare system to identify patients with UC and CRC. Read More

View Article
June 2018
2 Reads

Hormone Replacement Therapy and Colorectal Cancer Incidence and Mortality in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Clin Colorectal Cancer 2018 Jun 12;17(2):e281-e288. Epub 2018 Jan 12.

Department of Surgery, New York-Presbyterian Hospital/Weill Cornell Medicine, New York, NY; Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, NY.

Introduction: Hormone replacement therapy has been shown to reduce colorectal cancer incidence, but its effect on colorectal cancer mortality is controversial. The objective of this study was to determine the effect of hormone replacement therapy on survival from colorectal cancer.

Patients And Methods: We performed a secondary analysis of data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, a large multicenter randomized trial run from 1993 to 2001, with follow-up data recently becoming mature. Read More

View Article
June 2018
5 Reads

Cardiorespiratory Fitness and Body Composition Responses to Different Intensities and Frequencies of Exercise Training in Colorectal Cancer Survivors.

Clin Colorectal Cancer 2018 Jun 11;17(2):e269-e279. Epub 2018 Jan 11.

School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, QLD, Australia.

Introduction: Deteriorations in cardiorespiratory fitness (V˙o) and body composition are associated with poor prognosis after colorectal cancer treatment. However, the optimal intensity and frequency of aerobic exercise training to improve these outcomes in colorectal cancer survivors is unknown.

Patients And Methods: This trial compared 8 weeks of moderate-intensity continuous exercise (MICE; 50 minutes; 70% peak heart rate [HR]; 24 sessions), with high-intensity interval exercise (HIIE; 4 × 4 minutes; 85%-95% HR) at an equivalent (HIIE; 24 sessions) and tapered frequency (HIIE-T; 16 sessions) on V˙o and on lean and fat mass, measured at baseline, 4, 8, and 12 weeks. Read More

View Article
June 2018
3 Reads

LGALS4, CEACAM6, TSPAN8, and COL1A2: Blood Markers for Colorectal Cancer-Validation in a Cohort of Subjects With Positive Fecal Immunochemical Test Result.

Clin Colorectal Cancer 2018 Jun 12;17(2):e217-e228. Epub 2017 Dec 12.

Department of Experimental, Diagnostic and Specialty Medicine, Unit of Histology, Embryology and Applied Biology, University of Bologna, Bologna, Italy. Electronic address:

Background: A noninvasive blood test for the early detection of colorectal cancer (CRC) is highly required. We evaluated a panel of 4 mRNAs as putative markers of CRC.

Materials And Methods: We tested LGALS4, CEACAM6, TSPAN8, and COL1A2, referred to as the CELTiC panel, using quantitative reverse transcription polymerase chain reaction, on subjects with positive fecal immunochemical test (FIT) results and undergoing colonoscopy. Read More

View Article
June 2018
3 Reads

A Phase I Study of Irinotecan, Capecitabine (Xeloda), and Oxaliplatin in Patients With Advanced Colorectal Cancer.

Clin Colorectal Cancer 2018 Jun 15;17(2):e257-e268. Epub 2017 Dec 15.

Digestive Oncology Unit, Department of Gastroenterology, Universitair Ziekenhuis Leuven, Leuven, Belgium.

Background: The objective of the present phase I study was to define the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of irinotecan, capecitabine, and oxaliplatin given in combination (IXO regimen) to patients with previously untreated, unresectable advanced or metastatic colorectal cancer (CRC).

Patients And Methods: Patients received oxaliplatin followed by irinotecan as intravenous infusions on day 1, with oral capecitabine taken twice daily (BID) on days 2 to 15 of a 3-week cycle. The dose ranges were explored as follows: oxaliplatin, 75 to 120 mg/m; irinotecan, 160 to 230 mg/m; capecitabine, 750 to 1000 mg/m BID. Read More

View Article
June 2018
4 Reads

Two Months of Therapy: A Case of Pathologic Complete Response to Chemoimmunotherapy in a Patient With Metastatic Colorectal Cancer.

Clin Colorectal Cancer 2018 Jun 13;17(2):e229-e232. Epub 2017 Dec 13.

Department of Clinical Medicine, Indiana University Melvin Bren Simon Cancer Center, Indianapolis, IN. Electronic address:

View Article
June 2018
3 Reads
2.91 Impact Factor

Visceral Thromboses in Pancreas Adenocarcinoma: Systematic Review.

Clin Colorectal Cancer 2018 Jun 12;17(2):e207-e216. Epub 2017 Dec 12.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell Medicine, New York, NY. Electronic address:

Within gastrointestinal malignancies, primary hepatocellular carcinoma and pancreatic ductal adenocarcinoma (PDAC) are frequently associated with visceral thromboses (VT). Thrombus formation in the portal (PVT), mesenteric (MVT), or splenic vein (SVT) system leads to portal hypertension and intestinal ischemia. VT in PDAC may convey a risk of increased distal thrombosis and poses therapeutic uncertainty regarding the role of anticoagulation. Read More

View Article
June 2018
5 Reads